GW
PETX

Glenn Welling’s Aratana Therapeutics, Inc. PETX Stock Holding History

Glenn Welling’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,417,149
Closed -$8.7M – 12
2019
Q1 		$8.7M Sell
2,417,149
-1,070,000
-31% -$4.64M 1.22% 11
2018
Q4 		$21.4M Sell
3,487,149
-577,930
-14% -$3.53M 3.96% 9
2018
Q3 		$23.7M Buy
4,065,079
+1,665,079
+69% +$8.32M 3.33% 8
2018
Q2 		$10.2M Buy
2,400,000
+400,000
+20% +$2.02M 1.28% 11
2018
Q1 		$8.82M Buy
+2,000,000
New +$8.92M 1.2% 11

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $16.7B AUM 35.96% 1-Year Est. Return

Glenn Welling's PETX Position: Q2 2019 in Review

Glenn Welling sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 2,417,149 shares — an estimated $8.7M sold.

Glenn Welling first reported a position in PETX in Q1 2018 and held it in 5 quarters. The position peaked at $23.7M in Q3 2018. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

  • Glenn Welling reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Glenn Welling sold 2,417,149 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $8.7M.
  • Glenn Welling first reported a position in Aratana Therapeutics, Inc. in Q1 2018 and held it in 5 quarters.
  • Glenn Welling's Aratana Therapeutics, Inc. position peaked at $23.7M in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Engaged Capital's 13F filing for Q2 2019, filed 14 Aug 2019.